PET/CT-Guided Neoadjuvant Tislelizumab Plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis

Key Points

• The research aims to evaluate the effectiveness of tislelizumab combined with chemotherapy/chemoradiotherapy as a neoadjuvant treatment for resectable esophageal cancer.
• Utilized PET/CT scanning to guide treatment decisions.
• Administered tislelizumab alongside chemotherapy or chemoradiotherapy.
• Compared outcomes between PET-guided responders and nonresponders.
• Achieved promising pathological complete response (pCR) rates.
• Demonstrated favorable survival outcomes in participants.
• Maintained a tolerable safety profile across treatment groups.